Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): Sorafenib treatment and safety in U.S. patients with Child-Pugh B status.
Bilal Piperdi
Honoraria - Bayer/Onyx
Brendan McGuire
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
Parvez Mantry
Consultant or Advisory Role - Bayer/Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer/Onyx
Robert C. G. Martin
Honoraria - Bayer/Onyx
Pierre Michel Gholam
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx (I)
Jorge A. Marrero
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Research Funding - Bayer/Onyx; Bristol-Myers Squibb
Jeff H. Geschwind
Consultant or Advisory Role - Bayer; Bayer; Biocompatibles International; Biocompatibles International; Guerbet; Guerbet; Nordion; Nordion
Research Funding - Bayer; Bayer; Biocompatibles International; Biocompatibles International; CeloNova; CeloNova; ContextVision; ContextVision; Genentech; Genentech; Nordion; Nordion; Phillips Medical; Phillips Medical; RSNA; RSNA
Alan Paul Venook
Research Funding - Bayer/Onyx
Arun Sanyal
Employment or Leadership Position - AASLD (U); AASLD (U)
Consultant or Advisory Role - Onyx (U); Onyx (U)
Research Funding - Bayer/Onyx; Bayer/Onyx